4/A: Nexalin Technology Insider Filing: Elson and Osser Report Beneficial Ownership Changes

Marilyn Elson and Leonard Osser, both connected to Nexalin Technology, report changes in their beneficial ownership, including transactions involving common stock warrants.

Summary

• Marilyn Elson, a director and 10% owner of Nexalin Technology, filed an amended Form 4 to report changes in beneficial ownership.
• The earliest transaction date reported is September 28, 2022.
• The filing includes information on common stock warrants with an exercise price of $4.15.
• Elson reports owning 136,000 shares of common stock directly.
• Leonard Osser, also listed as other and spouse, is included in the joint filing.
• The filing indicates shared voting and dispositive power with spouse Leonard Osser.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be a signal to investors.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency in insider trading activities.
• Similar filings are made by insiders at companies like Medtronic (MDT) and Boston Scientific (BSX) whenever they trade in their company's stock.

Stakeholder Impact

• Shareholders may use this information to assess the confidence of insiders in the company's prospects.

Key Dates